Clinical trials: Healthy Volunteer, Type 2 Diabetes
Healthy Volunteers, Insulin Resistance
Polyphenols and Insulin Resistance
Diet and nutrition play an essential role in the development and the clinical expression of the most common health problems. Overeating and obesity induce oxidative stress, which has been proposed to be a pathogenic mechanism…
- Conditions
- Healthy Volunteers, Insulin Resistance, Type 2 Diabetes (T2D)
- Trial name
- POLYOXRESIST (NCT01478841)
- Testing
- polyphenol
- Where
- France
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Diabetes Mellitus, Type 2
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
This study will use scintigraphy techniques to measure gastric emptying rate of liquid and solid food at baseline and after administration of GSK716155 or placebo.
- Trial name
- NCT00537719
- Testing
- GSK716155
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Drug-drug Interaction Between Simvastatin and SHR3824
the purpose of thr study is to investigate the potential interation between multiple oral doses of SHR3824 and single oral dose of Simvastatin in healthy adult volunteers.
- Trial name
- NCT03329118
- Testing
- SHR3824, Simvastatin
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Bioequivalence Study for Fixed Dose Combination Zemimet® SR Tab. 50/1000 and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.
To determine and compare the rate and extent of absorption of gemigliptin/metformin hydrochloride sustained release 50/1000 mg FDC tablet (Zemimet® SR Tab.
- Trial name
- NCT04317703
- Testing
- Gemigliptin tartrate sesquihydrate and metformin, gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release
- Where
- Thailand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- LG Chem
Diabetes Mellitus, Type 2
Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes
This study will look at the skin accumulation of vildagliptin and its two major metabolites, LAY151 and LAF237-O-Glucuronide, after vildagliptin 50 mg given orally twice a day for 10 days in both healthy volunteers and patients…
- Trial name
- NCT00633997
- Testing
- Vildagliptin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Novartis
Healthy, Type 2 Diabetes Mellitus
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multiple doses of LY3938577 in…
- Trial name
- NCT06132126
- Testing
- LY3938577, Insulin degludec
- Where
- 3 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects
Single ascending dose first time in human study for GZR18 in healthy subjects
- Trial name
- NCT05328726
- Testing
- GZR-18
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Healthy, Diabetes Mellitus, Type 2
A Study of LC542019 in Healthy Subjects and Subjects With T2DM
to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics in healthy subjects and subjects with type 2 diabetes (T2DM).
- Trial name
- NCT06333977
- Testing
- LC542019
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- LG Chem
Microangiopathy, Diabetic, Polyphenol
Macro- and Microvascular Response to Cocoa Flavanols in Healthy and Type 2 Diabetes
The greatest challenge in our ageing society are cardiovascular diseases such as stroke, heart attack, peripheral artery disease of the legs with non-healing wounds (ulcers), or diabetes.
- Conditions
- Microangiopathy, Diabetic, Polyphenol, Optical Tomography, Vascular Endothelium
- Trial name
- NCT05449782
- Testing
- Cocoa flavanol
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Type 2 Diabetes
A Relative Bioavailability Study of HRS9531 in Healthy Subjects
The purpose of this study is to evaluate the relative bioavailability of the new formulation of HRS9531 injection between the original formulation of HRS9531 injection.
- Trial name
- NCT05893576
- Testing
- HRS9531
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers
This trial is conducted in the United States of America (USA). The aim of this trial is to compare repaglinide and metformin as co-administered tablets and as a combination tablet.
- Trial name
- NCT01490658
- Testing
- repaglinide, metformin, repaglinide and metformin combination tablet
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.
Bioequivalence Study of Empagliflozin Tablets and Jardiance® Under Fasting and Fed Conditions in Chinese Healthy Volunteers.
- Trial name
- NCT03771781
- Testing
- Empagliflozin Tablets, Empagliflozin Tab 25 MG
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Type 2 Diabetes Mellitus
Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus
DS-1150b is being developed by Daiichi Sankyo for the treatment of Type 2 Diabetes Mellitus. This is a Phase I, single-blind (subjects and principal investigator blinded, Sponsor unblinded), placebo-controlled, randomized…
- Trial name
- NCT02004678
- Testing
- DS-1150b
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo
Healthy Volunteers Type 2 Diabetes
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men
This study looks at how the new medicine called NNC0480-0389 works in the body of Japanese men when it is given together with semaglutide.
- Trial name
- NCT04878406
- Testing
- NNC0480-0389, Semaglutide
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Food-drug Interaction Study of SY-004 in Healthy Subjects
A randomized, open, two cycle, double crossover, single center study was conducted to evaluate the effect of high-fat diet on the pharmacokinetics of SY-004 in healthy subjects
- Trial name
- NCT04907006
- Testing
- SY-004 capsule
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Type 2 Diabetes Mellitus
Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients
This study will evaluate the pharmacokinetics of vildagliptin (LAF237) and its metabolites in patients with mild renal impairment compared to their sex, age and weigh based healthy volunteer counterparts.
- Trial name
- NCT00572650
- Testing
- vildagliptin
- Where
- Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-398
- Trial name
- NCT04869800
- Testing
- CKD-398, CKD-501, D745
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2
The Effects of LY2409021 on the Liver
This is a study that involves multiple doses of study drug (60 mg of LY2409021, 15 mg of LY2409021 or placebo) taken as capsules by mouth on a daily basis for 28 days.
- Trial name
- NCT01588366
- Testing
- LY2409021
- Where
- Singapore
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects
The purpose of this research study is to look at concentrations of GSK189075 in blood when different long and short acting forms of the drug are taken by mouth.
- Trial name
- NCT00559884
- Testing
- GSK189075 (Modified and immediate release formulations)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type II Diabetes
Clinical Trial for PB-119 in Healthy Subjects (Phase I)
GLP-1 analogues have been widely used because of their unique advantages (no risk of hypoglycemia) due to their glucose dependent mechanism.
- Trial name
- NCT02084251
- Testing
- PB-119
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- PegBio Co., Ltd.